Estudio piloto: Impacto del farmacéutico en la identificación y evaluación de interacciones potenciales fármaco-fármaco en prescripciones de pacientes hospitalizados de Medicina Interna
Introduction. Potential drug interactions can contribute to therapeutic failures and/or possible iatrogenesis when prescribed with two or more drugs that may interact. In Mexico, there are few studies that allow establishing the current panorama and their importance in the validation of the pres...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | español |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | https://dialnet.unirioja.es/servlet/oaiart?codigo=7768287 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Introduction. Potential drug interactions can contribute to therapeutic
failures and/or possible iatrogenesis when prescribed with two or
more drugs that may interact. In Mexico, there are few studies that
allow establishing the current panorama and their importance in the
validation of the prescription by the pharmacist.
Objective. To evaluate the impact of the pharmacist in the identification
and evaluation of potential drug-drug interactions in prescriptions of
hospitalized patients of Internal Medicine
Material and methods. Observational, cross-sectional, retrospective,
continuous inclusion study. Complete prescription sheets, indistinct
diagnosis, and ≥2 prescribed drugs were evaluated. Interactions were
detected through the micromedex 2.0 software. They were grouped by
frequency, severity and pharmacological group. Secondarily, potential
laboratory parameter drug interactions were recorded.
Results. In 94 patients, 743 different medications, an average of 8±3
medications/patient, with analgesics being the most prescribed. 141
potential drug-drug interactions (IPFF) were found. 47.9 % of the
patients presented some interaction, of which 38.3 % were severe;
percentage that decreased to 11.4 % after pharmacist evaluation as
clinically relevant. Potential laboratory parameter drug interactions
were identified, 8.3 % were severe. An index of 1.5 IPFF/patient las observed, which was reduced to 0.20 IPFF/patient
after their evaluation by the pharmacist.
Conclusions. 47.9 % presented IPFF, which,
regardless of its severity, constitutes an unrecognized
problem during hospital care. Identifying those
potential interactions, validating their clinical
relevance by the clinical pharmacist, showed a
reduction of 88.7 % of the observed interactions;
allowing for more targeted surveillance. |
|---|